8-K: GoodRx Appoints Wendy Barnes as New CEO and President, Effective January 1, 2025

GoodRx Holdings, Inc. has announced the appointment of Wendy Barnes as its new Chief Executive Officer and President, effective January 1, 2025, succeeding interim CEO Scott Wagner.

Summary

• GoodRx Holdings, Inc. has appointed Wendy Barnes as the new Chief Executive Officer and President, effective January 1, 2025.
• Ms. Barnes will also join the Board of Directors as a Class I director with a term expiring at the 2027 Annual Meeting of Stockholders.
• Prior to this appointment, Ms. Barnes served as CEO of RxBenefits, Inc. and held various roles at Express Scripts Holding Company.
• Ms. Barnes's employment agreement includes an annual base salary of $825,000 and eligibility for an annual cash incentive bonus targeted at 100% of her base salary.
• She will also receive a one-time signing bonus of $550,000.
• Ms. Barnes will be granted a restricted stock unit award and a stock option, each valued at $9,000,000, and an additional restricted stock unit award valued at $2,000,000 under the company's 2020 Incentive Award Plan.
• These equity awards will vest over time, with initial vesting occurring on January 15, 2026, and subsequent vesting on a quarterly basis.
• The agreement includes severance benefits in the event of termination without cause or resignation for good reason, including up to 18 months of base salary, pro-rated target bonus, and continued health coverage.

Sentiment

Score: 7

Explanation: The document is generally positive, highlighting the appointment of a new CEO with a strong background. The compensation package is generous, which could be seen as both positive and potentially risky. The overall sentiment is optimistic about the future leadership of the company.

Positives

• The appointment of a new CEO with significant experience in the healthcare industry is a positive step for the company.
• The compensation package for the new CEO is competitive and includes both cash and equity incentives.
• The vesting schedule for the equity awards is designed to align the CEO's interests with the long-term success of the company.
• The severance package provides a safety net for the CEO in the event of termination without cause or resignation for good reason.
• The inclusion of a best pay provision under Section 280G of the Internal Revenue Code ensures the CEO receives the best after-tax treatment of parachute payments.

Negatives

• The company will incur significant costs related to the CEO's compensation package, including the signing bonus and equity awards.
• The severance package could be costly if the CEO's employment is terminated without cause or if she resigns for good reason.
• The company is relying on the new CEO to improve performance and achieve its goals, which carries inherent risk.

Risks

• There is a risk that the new CEO may not be successful in improving the company's performance.
• The company may face challenges in integrating the new CEO into the existing management team.
• The company may face challenges in achieving the performance goals required for the CEO to earn her full incentive bonus.
• There is a risk that the company may need to pay significant severance costs if the CEO's employment is terminated.

Future Outlook

The company expects Wendy Barnes to commence her employment on January 1, 2025, and to lead the company in achieving its strategic goals. The company will also grant her equity awards on the first trading day of the first open window following her start date.

Management Comments

• The Board of Directors believes Ms. Barnes is qualified to serve on our Board due to her significant leadership experience in the healthcare industry.

Industry Context

This announcement is significant as it brings in a new leader with extensive experience in pharmacy benefit management, a key area for GoodRx's business. The appointment of a seasoned executive like Ms. Barnes could signal a strategic shift or renewed focus for the company in a competitive healthcare market.

Comparison to Industry Standards

• The compensation package for Wendy Barnes, including a base salary of $825,000, a $550,000 signing bonus, and $18 million in initial equity awards, is competitive with other publicly traded healthcare technology companies.
• For example, CEOs at similar companies like Teladoc Health or Livongo (prior to its merger with Teladoc) have received comparable compensation packages, often including a mix of base salary, bonuses, and significant equity grants.
• The vesting schedule for the equity awards, with 25% vesting after one year and the remainder vesting quarterly, is also standard practice in the industry to incentivize long-term performance.
• The severance package, including up to 18 months of base salary and continued health coverage, is also in line with industry norms for executive-level employment agreements.
• The inclusion of a 'best pay' provision under Section 280G is a common practice to protect executives from excise taxes on change-in-control payments.

Management Changes

Stakeholder Impact

• Shareholders may react positively to the appointment of a new CEO with a strong track record.
• Employees may be impacted by the change in leadership and the new strategic direction of the company.
• Customers may benefit from the new CEO's focus on improving the company's products and services.
• Suppliers and creditors may be impacted by any changes in the company's business strategy.

Next Steps

• Wendy Barnes will commence her employment as CEO and President on January 1, 2025.
• The company will grant Ms. Barnes her initial equity awards on the first trading day of the first open window following her start date.
• The Board of Directors will work with Ms. Barnes to establish performance goals for the annual cash incentive bonus.

Key Dates

Keywords

CEO, Chief Executive Officer, Wendy Barnes, GoodRx, Executive Appointment, Employment Agreement, Compensation, Equity Awards, Severance, Board of Directors